Literature DB >> 9193314

Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.

G F Harding.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9193314      PMCID: PMC2126860     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  20 in total

1.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

2.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

3.  Tangent screens are still useful in the assessment of vigabatrin induced visual field defects.

Authors:  J A Olson; A T Purdie; R J Coleman
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

4.  Retinal function and histopathology in rabbits treated with Topiramate.

Authors:  S Kjellström; A Bruun; B Isaksson; T Eriksson; S Andréasson; V Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-11-18       Impact factor: 2.379

5.  [Asymptomatic concentric visual field deficits and optic nerve atrophy].

Authors:  S Mennel; S Schulze; C H Meyer
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

Review 6.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.

Authors:  V Ponjavic; S Andréasson
Journal:  Doc Ophthalmol       Date:  2001-01       Impact factor: 2.379

8.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

9.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

10.  Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.

Authors:  Vesna Ponjavic; Lotta Gränse; Sten Kjellström; Sten Andréasson; Anitha Bruun
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.